Lymph Tech

Lymph Tech, a biotechnology start-up created in January 2024, has developed a treatment for secondary lymphedema, a painful and disabling pathology that cannot yet been treated. Phase I/IIa will begin in September 2024. Lymph Tech is the result of the collaboration between Dr. Garmy-Susini DR1 at Inserm Toulouse (where the first patents reside) and Dr. Malloizel Delaunay PH at the Rangueuil University Hospital, but also the culmination of a European Theralymph project which has made it possible to carry out the project and the product (code name Apernavec); The product is particularly innovative technically because it is based on mRNA, and the encapsulation of a dual therapy in a single vector. Lymph Tech is part of a medium-term R&D perspective in the fields of edema and other diseases of the vascular system.

Medicine

0.00 K€